Literature DB >> 23689683

siRNA-Act1 inhibits the function of IL-17 on lung fibroblasts via the NF-κB pathway.

Zhaoxing Dong1, Yanni Yang, Tao Zhang, Yongxia Li, Qinxin Kang, Wen Lei, Yu Cao, Xiaoqun Niu, Dianhua Wang, Wenlin Tai.   

Abstract

BACKGROUND: Interleukin (IL)-17-producing T lymphocytes play a role in pulmonary fibrosis, but the possible mechanism of IL-17 on lung fibroblasts remains uncertain.
OBJECTIVES: To explore the role and possible mechanism of IL-17 on lung fibroblasts.
METHODS: A mouse model of pulmonary fibrosis was established by intratracheal administration of 5 mg/kg bleomycin. At 14 days following bleomycin administration the pulmonary fibroblasts were isolated, cultured and identified. siRNA for activator 1 (Act1) were transfected into lung fibroblasts, which were cocultured with IL-17. The NF-κB pathway was detected for IL-17 on the lung fibroblasts.
RESULTS: IL-17R was increased significantly at 14 days in the bleomycin-induced pulmonary fibroblast model, exogenous IL-17 significantly promoted the proliferation of the pulmonary fibroblasts in primary culture and obviously increased the expression of α-smooth muscle actin and type I and type III collagen in the fibroblasts. We found that IL-17 rapidly activated the NF-κB signaling pathway through activated phosphorylated p65 and IκB, and all roles of IL-17 on lung fibroblasts were inhibited under the interference for the expression of Act1 in lung fibroblasts.
CONCLUSION: IL-17 may directly promote the proliferation, transformation and collagen synthesis of lung fibroblasts via the NF-kB signaling pathway, which can be inhibited by the interference for the expression of Act1.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689683     DOI: 10.1159/000348403

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  6 in total

1.  Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension.

Authors:  Levi D Maston; David T Jones; Wieslawa Giermakowska; Tamara A Howard; Judy L Cannon; Wei Wang; Yongyi Wei; Weimin Xuan; Thomas C Resta; Laura V Gonzalez Bosc
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-02-17       Impact factor: 5.464

Review 2.  The Yin and Yang of IL-17 in Systemic Sclerosis.

Authors:  Lanxuan Wei; David Abraham; Voon Ong
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

Review 3.  IL-17 in the lung: the good, the bad, and the ugly.

Authors:  Stephen J Gurczynski; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

4.  IL-27 alleviates the bleomycin-induced pulmonary fibrosis by regulating the Th17 cell differentiation.

Authors:  Zhaoxing Dong; Xin Lu; Yanni Yang; Tao Zhang; Yongxia Li; Yanlin Chai; Wen Lei; Changbo Li; Li Ai; Wenlin Tai
Journal:  BMC Pulm Med       Date:  2015-02-18       Impact factor: 3.317

5.  Translational targeting of inflammation and fibrosis in frozen shoulder: Molecular dissection of the T cell/IL-17A axis.

Authors:  Moeed Akbar; Lindsay A N Crowe; Michael McLean; Emma Garcia-Melchor; Lucy MacDonald; Kristyn Carter; Umberto G Fazzi; David Martin; Angus Arthur; James H Reilly; Iain B McInnes; Neal L Millar
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-28       Impact factor: 11.205

Review 6.  Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis.

Authors:  Mahbub Hasan; Nidhan Chandra Paul; Shamrat Kumar Paul; Abu Saim Mohammad Saikat; Hafeza Akter; Manoj Mandal; Sang-Suk Lee
Journal:  Molecules       Date:  2022-02-22       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.